Digest Network Come funziona
Network
/
Società
Es
Non verificato

Estrella Immunopharma, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

23 comunicati stampa

Guarda tutti i comunicati
26/10/2026
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Mercato del lavoro
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
15/10/2026
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
14/10/2026
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
11/08/2026
Industria
Università
Biologia
Biotecnologia
Scuola/Istruzione
Salute
Sanità
Farmaceutica
Oncologia
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
03/08/2026
Mercato del lavoro
Scienza
Biotecnologia
Medicina - Varie
Università
Farmaceutica
Salute
Scuola/Istruzione
Oncologia
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
29/07/2026
Mercato del lavoro
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
24/07/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Eventi
Biotecnologia
Farmaceutica
Salute
Oncologia
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
23/03/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0
09/02/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Fonte
Estrella Immunopharma, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0